Lixte Biotechnology Holdings Management

Management criteria checks 2/4

Lixte Biotechnology Holdings' CEO is Bas van der Baan, appointed in Sep 2023, has a tenure of 1.17 years. directly owns 0.48% of the company’s shares, worth $22.10K. The average tenure of the management team and the board of directors is 1.6 years and 4.9 years respectively.

Key information

Bas van der Baan

Chief executive officer

US$624.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	1.2yrs
CEO ownership	0.5%
Management average tenure	1.6yrs
Board average tenure	4.9yrs

Recent management updates

Recent updates

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Jul 20

Lixte Biotechnology starts enrollment in early-stage lung cancer study

Jun 02

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Feb 25

CEO

Bas van der Baan (52 yo)

1.2yrs

Tenure

US$623,981

Compensation

Mr. Bastiaan van der Baan, also known as Bas, MSc, served as Independent Director of Lixte Biotechnology Holdings, Inc. from June 17, 2022 until September 26, 2023 and serves as its Chief Executive Officer...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Bastiaan van der Baan	President	1.2yrs	US$623.98k	0.48% $ 22.1k
Robert Weingarten	VP & CFO	4.3yrs	US$175.00k	0% $ 0
Eric Forman	VP & COO	2yrs	US$200.00k	2.08% $ 96.4k
Johannes Henricus Schellens	Chief Medical Officer	less than a year	no data	0.056% $ 2.6k

1.6yrs

Average Tenure

60yo

Average Age

Experienced Management: LIXT's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Bastiaan van der Baan	President	2.4yrs	US$623.98k	0.48% $ 22.1k
Daniel Von Hoff	Member of Scientific Advisory Committee	10.8yrs	no data	no data
Stephan Forman	Director	8.5yrs	US$70.63k	0.33% $ 15.4k
René Bernards	Independent Director	2.4yrs	US$62.50k	1.11% $ 51.5k
Yun Yen	Independent Director	6.3yrs	US$78.13k	0.23% $ 10.8k
Regina Brown	Independent Director	3.5yrs	US$78.13k	0.028% $ 1.3k

4.9yrs

Average Tenure

70yo

Average Age

Experienced Board: LIXT's board of directors are considered experienced (4.9 years average tenure).

Lixte Biotechnology Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Recent updates

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Dec 19, 2024

Lixte Biotechnology Holdings Receives an Extension Through February 18, 2025 to Regain Compliance with the Stockholders’ Equity Requirement

First Patient Dosed with Lixte Biotechnology Holdings, Inc.’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Lixte Biotechnology Holdings, Inc. Reports Findings Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings, Inc. Announces Executive Changes

New major risk - Share price stability

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

New minor risk - Shareholder dilution

New major risk - Share price stability

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Lixte Biotechnology starts enrollment in early-stage lung cancer study

Independent Director has left the company

Lixte Biotechnology Holdings, Inc. to Showcase Its Anti-Cancer Therapy Enhancer LB-100 At the Virtual Annual Roth Capital Conference

New 90-day high: US$5.58

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

New 90-day low: US$3.05

Lixte Biotechnology Holdings, Inc. and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’S Lead Compound Lb-100 to Treat Small Cell Lung Cancer

New 90-day low: US$3.14

New 90-day low: US$3.59

New 90-day low: US$3.60

New 90-day low: US$3.65

Lixte Biotechnology Holdings Deleted from Other OTC

New 90-day low: US$3.74

Lixte Biotechnology Holdings, Inc. has completed an IPO in the amount of $5.7 million.

Lixte Biotechnology Holdings, Inc. has filed an IPO in the amount of $10.668 million.

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age